Novo Nordisk ® ney is complex and underscores vo Nordisk to be successful Hurdles mplex tests and mited screening/ iagnosing skills Lack of prognostic markers and simple tests Limited DMT options Few patients receiving diagnosis Market preparation priorities Increase diagnosis rate Evidence generation • Support NITs development, e.g. blood-based/digital biomarkers • Increase AD education and access to screening tools for PCPs and HCP insight Low expected investment level • Evidence to better understand the • impact of delaying disease progression • role of neuroinflammation in disease progression ysicians; NITs: Non-invasive diagnostics; HCP: Healthcare professional
Download PDF file